FOXO1 and embryonal rhabdomyosarcoma: ARMS has been described as more aggressive having a prognostic disadvantage compared to ERMS, specifically in the majority subset expressing the fusion oncoprotein PAX3-FOXO1 (or less commonly PAX7-FOXO1) (3).